Search
3 articles for “mcr gene”
-
Global Emergence of mcr-mediated Colistin Resistance in Gram-negative Bacteria: Focusing the Current Status in India Under One Health Lens
Abstract: In the global crisis of antimicrobial resistance (AMR), colistin has been revived as a last resort treatment option for multidrug-resistant (MDR) Gram-negative bacterial infections. Rapid dissemination of mobilized colistin resistance (mcr) genes among Gram-negative bacterial pathogens is alarming the healthcare fraternity throughout the world, especially in developing countries such as India compromises infection prevention practices and reduces colistin efficacy during medical emergencies.. Several developed countries have implemented strict regulations on …
Published in Research and Reviews: A Journal of Microbiology and Virology · Vol. 12, Issue 3, 2022 · pp. 6–18 Read article
-
Review: Virulence factors, resistance genes and pathogenicity of Moraxella catarrhalis
Abstract: An estimated 2-4 million cases of chronic obstructive pulmonary disease(COPD) in adults are exacerbated by Moraxella catarrhalis annually in the US, making it a pathogen of increasing significance for respiratory tract infections. It often colonizes the nasopharynx without causing any symptoms and an opportunistic bacterial infection of the respiratory mucosa that is exclusive to humans. In our study, we reviewed references about the important virulence factors that M. catarrhalis possess …
Published in Recent Trends in Infectious Diseases · Vol. 2, Issue 1, 2025 · pp. 33–40 Read article
-
Pharmacological Review On Enzalutamide
Abstract: A key therapeutic option in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), is Enzalutamide, a second-generation anti androgen drug. Enzalutamide, discovered by Charles Sawyer and Michael Jung at the University of California, Los Angeles, was developed and Food and Drug Administration (FDA)-approved in 2012. Its therapeutic significance was further solidified with subsequent extensions in indications to encompass metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. …
Published in Trends in Drug Delivery · Vol. 11, Issue 2, 2024 · pp. 7–15 Read article